Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure

Figure 1

Study visits and study medication of the enrolled participants. 50 patients were included in the study and in the initial study visit; ivabradine was started on a dosage of 2 × 5 mg. In the 3-month follow-up, dosage was adjusted to 2 × 7.5 mg if heart rate was still above 60 bpm. The study ended with the 6-month follow-up. 17 patients were excluded due to side effects, so 33 patients completed the study. bpm = beats per minute, CHF = chronic heart failure, and CM = cardiomyopathy.